RxDoctor Payments Data

Wafa Musa Popeney, DO

Family Medicine · Sugar Land, TXNPI 1487670543

Payments from drug & device makers

$7,653in general payments, 2019–2025

Across 368 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$786
  • Acadia Pharmaceuticals Inc$466
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$414
  • Novartis$413
  • Lilly USA, LLC$361
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$7,49098%
  • Education$1632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,653 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$42,831
Medicare patients
161
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$46,191
OzempicSemaglutide26$39,880
JardianceEmpagliflozin35$29,127
JanumetSitagliptin Phos/Metformin Hcl14$20,847
JanuviaSitagliptin Phosphate16$19,647
TradjentaLinagliptin15$15,634
MyrbetriqMirabegron15$13,885
EliquisApixaban13$12,438
Memantine Hcl ErMemantine Hcl11$3,882
Levothyroxine Sodium190$1,961
Citalopram HbrCitalopram Hydrobromide25$1,904
Levetiracetam12$1,779
Olmesartan Medoxomil115$1,679
SynthroidLevothyroxine Sodium22$1,455
Albuterol Sulfate HfaAlbuterol Sulfate65$1,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$361$46,19134 claims
MerckJanumet, Januvia$12$40,49430 claims
Novo NordiskOzempic$55$39,88026 claims
Astellas Pharma US IncMyrbetriq$14$13,88515 claims
PfizerEliquis$140$12,43813 claims
AbbVieSynthroid$1,529$1,45522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →